Global Neoantigen Vaccine Industry Outlook 2021: Overview, Opportunities, Key Companies and Forecast to 2027
Report Code: KNJ1028195 No. of Pages: 148 Category: Pharmaceuticals and Healthcare
Publisher: Date of Publish:
Publisher: Date of Publish:
Executive Summary
According to GRD Survey data, the global Neoantigen Vaccine market was valued at million US$ in 2020 and is expected to reach million US$ by the end of 2027, growing at a CAGR of % in the forecast period between 2021 and 2027.
This report studies the Neoantigen Vaccine market dynamics from angles such as new entries, mergers and acquisitions, fundings, exit and major technology breakthroughs. Market performance is evaluated through market size (value and volume) by players, regions, product types and end industries. This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter's Five Forces Analysis.
Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of Neoantigen Vaccine in these regions, from 2016 to 2027, covering
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Italy, Spain and Russia, etc.)
Asia-Pacific (China, Japan, Korea, Southeast Asia, India, Australia)
South America (Brazil, Argentina, Colombia, etc.)
Middle East and Africa (Turkey, Saudi Arabia, South Africa, etc.)
Market Snapshot, By Product Type
Personalized Vaccine
Off-the shelf Vaccine
Market Snapshot, By Application
Lung Cancer
Melanoma Cancer
Gastrointestinal Cancer
Brain Cancer
Others
Main Market Players Analyzed in this report, including:
ZIOPHARM Oncology
Vaximm AG
Vaccibody AS
Roche Holding AG
Pfizer
OSE Immunotherapeutics
Novogene
Nouscom
Moderna
Merck & Co Inc
Medigene AG
ISA Pharmaceuticals
Gritstone Bio
Genocea Biosciences Inc
Eli Lilly and Company
BrightPath Biotherapeutics
BioNTech
Avidea Technologies
Agenus Inc
Advaxis
The study objectives of this report are:
To study and analyze the global Neoantigen Vaccine market size (value & volume) by company, key regions/countries, products and application, history data from 2016 to 2020, and forecast to 2027.
To understand industry structure of Neoantigen Vaccine market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To identify the key global Neoantigen Vaccine manufacturers and regional typical players, to define, describe and analyze their sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Neoantigen Vaccine market with respect to individual growth trends, future prospects, and their contribution to the total market.
To project the value and volume of Neoantigen Vaccine submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
In this study, the years considered to estimate the market size of Neoantigen Vaccine are as follows:
History Year: 2016-2020
Base Year: 2020
Estimated Year: 2021
Forecast Year 2021 to 2027
This report includes the estimation of market size in terms of value (million USD) and volume from top-down approach by analyzing major submarkets and their major driving factors, and verified from bottom-up approaches. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified from primary sources.
For the data information by region, company, type and application, 2020 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Key Stakeholders Considered in the study:
Raw material vendors
Distributors/traders/wholesalers/suppliers
Regulatory authorities, including government agencies and NGO
Commercial research & development (R&D) institutions
Importers and exporters
Government organizations, research organizations, and consulting firms
Trade/Industrial associations
End-use industries
Table of Contents
1 Market Definition & Scope
1.1 Definition & Scope
1.2 Neoantigen Vaccine Product Specifications
1.3 Main Events (Entry, M&A, Exit, Technology and Capital Activity)
1.4 Global Neoantigen Vaccine Market Performance and Outlook
2 Market Development Performance under COVID-19
2.1 Influencing Factors of Industry Development in the Next Five Years
2.1.1 Drivers
2.1.2 Restraints
2.1.3 Opportunities
2.2 Porter’s Five Forces Analysis
2.3 Comparison of Alternatives and Neoantigen Vaccine
3 Supply Chain and Manufacturing Cost Analysis
3.1 Supply Chain Analysis
3.2 Raw Materials and Key Suppliers Analysis
3.2.1 Raw Materials Introduction
3.2.1 Raw Materials Key Suppliers List
3.3 Neoantigen Vaccine Sales Channel and Distributors Analysis
3.3.1 Neoantigen Vaccine Sales Channel
3.3.2 Neoantigen Vaccine Distributors
3.4 Key Buying Industries/Consumers
3.4.1 Major Buyers in Lung Cancer
3.4.2 Major Buyers in Melanoma Cancer
3.5 Neoantigen Vaccine Manufacturing Cost Structure Analysis
4 Market Segment: by Type
4.1 Neoantigen Vaccine Type Introduction
4.1.1 Personalized Vaccine
4.1.2 Off-the shelf Vaccine
4.2 Global Neoantigen Vaccine Sales by Type 2016-2021
4.3 Global Neoantigen Vaccine Revenue by Type 2016-2021
4.4 Global Neoantigen Vaccine Price by Type 2016-2021
5 Market Segment: by Application
5.1 Neoantigen Vaccine Type Introduction
5.1.1 Lung Cancer
5.1.2 Melanoma Cancer
5.1.3 Gastrointestinal Cancer
5.1.3 Brain Cancer
5.1.4 Others
5.2 Global Neoantigen Vaccine Sales by Application 2016-2021
5.3 Global Neoantigen Vaccine Revenue by Application 2016-2021
5.4 Global Neoantigen Vaccine Price by Application 2016-2021
6 Marke Segment: by Region
6.1 Global Neoantigen Vaccine Market by Region
6.1.1 Global Neoantigen Vaccine Sales by Regions
6.1.2 Global Neoantigen Vaccine Revenue by Regions
6.2 North America Neoantigen Vaccine Market 2016-2021
6.3 Europe Neoantigen Vaccine Market 2016-2021
6.4 Asia Pacific Neoantigen Vaccine Market 2016-2021
6.5 South America Neoantigen Vaccine Market 2016-2021
6.6 Middle East and Africa Neoantigen Vaccine Market 2016-2021
7 North America
7.1 North America Neoantigen Vaccine Market by Country 2016-2021
7.1.1 North America Neoantigen Vaccine Sales by Country
7.1.2 North America Neoantigen Vaccine Revenue by Country
7.2 United States
7.3 Canada
7.4 Mexico
8 Europe
8.1 Europe Neoantigen Vaccine Market by Country 2016-2021
8.1.1 Europe Neoantigen Vaccine Sales by Country
8.1.2 Europe Neoantigen Vaccine Revenue by Country
8.2 Germany
8.3 France
8.4 UK
8.5 Italy
8.6 Russia
8.7 Spain
9 Asia Pacific
9.1 Asia Pacific Neoantigen Vaccine Market by Country 2016-2021
9.1.1 Asia Pacific Neoantigen Vaccine Sales by Country
9.1.2 Asia Pacific Neoantigen Vaccine Revenue by Country
9.2 China
9.3 Japan
9.4 Korea
9.5 Southeast Asia
9.6 India
9.7 Australia
10 South America
10.1 South America Neoantigen Vaccine Market by Country 2016-2021
10.1.1 South America Neoantigen Vaccine Sales by Country
10.1.2 South America Neoantigen Vaccine Revenue by Country
10.2 Brazil
10.3 Argentina
10.4 Colombia
11 Middle East and Africa
11.1 Middle East and Africa Neoantigen Vaccine Market by Country 2016-2021
11.1.1 Middle East and Africa Neoantigen Vaccine Sales by Country
11.1.2 Middle East and Africa Neoantigen Vaccine Revenue by Country
11.2 Turkey
11.3 Saudi Arabia
11.4 South Africa
12 Key Participants Company Information
12.1 ZIOPHARM Oncology
12.1.1 ZIOPHARM Oncology
Company Information
12.1.2 ZIOPHARM Oncology
Neoantigen Vaccine Product Portfolio, Specification and Application
12.1.3 ZIOPHARM Oncology
Neoantigen Vaccine Sales, Price, Revenue and Gross Margin (2019-2021)
12.1.4 ZIOPHARM Oncology
Key Development
12.2 Vaximm AG
12.2.1 Vaximm AG
Company Information
12.2.2 Vaximm AG
Neoantigen Vaccine Product Portfolio, Specification and Application
12.2.3 Vaximm AG
Neoantigen Vaccine Sales, Price, Revenue and Gross Margin (2019-2021)
12.2.4 Vaximm AG
Key Development
12.3 Vaccibody AS
12.3.1 Vaccibody AS
Company Information
12.3.2 Vaccibody AS
Neoantigen Vaccine Product Portfolio, Specification and Application
12.3.3 Vaccibody AS
Neoantigen Vaccine Sales, Price, Revenue and Gross Margin (2019-2021)
12.3.4 Vaccibody AS
Key Development
12.4 Roche Holding AG
12.4.1 Roche Holding AG
Company Information
12.4.2 Roche Holding AG
Neoantigen Vaccine Product Portfolio, Specification and Application
12.4.3 Roche Holding AG
Neoantigen Vaccine Sales, Price, Revenue and Gross Margin (2019-2021)
12.4.4 Roche Holding AG
Key Development
12.5 Pfizer
12.5.1 Pfizer
Company Information
12.5.2 Pfizer
Neoantigen Vaccine Product Portfolio, Specification and Application
12.5.3 Pfizer
Neoantigen Vaccine Sales, Price, Revenue and Gross Margin (2019-2021)
12.5.4 Pfizer
Key Development
12.6 OSE Immunotherapeutics
12.6.1 OSE Immunotherapeutics
Company Information
12.6.2 OSE Immunotherapeutics
Neoantigen Vaccine Product Portfolio, Specification and Application
12.6.3 OSE Immunotherapeutics
Neoantigen Vaccine Sales, Price, Revenue and Gross Margin (2019-2021)
12.6.4 OSE Immunotherapeutics
Key Development
12.7 Novogene
12.7.1 Novogene
Company Information
12.7.2 Novogene
Neoantigen Vaccine Product Portfolio, Specification and Application
12.7.3 Novogene
Neoantigen Vaccine Sales, Price, Revenue and Gross Margin (2019-2021)
12.7.4 OSE Immunotherapeutics
Key Development
12.9 Moderna
12.9.1 Moderna
Company Information
12.9.2 Moderna
Neoantigen Vaccine Product Portfolio, Specification and Application
12.9.3 Moderna
Neoantigen Vaccine Sales, Price, Revenue and Gross Margin (2019-2021)
12.9.4 Moderna
Key Development
12.8 Nouscom
12.8.1 Nouscom
Company Information
12.8.2 Nouscom
Neoantigen Vaccine Product Portfolio, Specification and Application
12.8.3 Nouscom
Neoantigen Vaccine Sales, Price, Revenue and Gross Margin (2019-2021)
12.8.4 Nouscom
Key Development
12.11 Medigene AG
12.11.1 Medigene AG
Company Information
12.11.2 Medigene AG
Neoantigen Vaccine Product Portfolio, Specification and Application
12.11.3 Medigene AG
Neoantigen Vaccine Sales, Price, Revenue and Gross Margin (2019-2021)
12.11.4 Medigene AG
Key Development
12.12 ISA Pharmaceuticals
12.12.1 ISA Pharmaceuticals
Company Information
12.12.2 ISA Pharmaceuticals
Neoantigen Vaccine Product Portfolio, Specification and Application
12.12.3 ISA Pharmaceuticals
Neoantigen Vaccine Sales, Price, Revenue and Gross Margin (2019-2021)
12.12.4 ISA Pharmaceuticals
Key Development
12.13 Gritstone Bio
12.13.1 Gritstone Bio
Company Information
12.13.2 Gritstone Bio
Neoantigen Vaccine Product Portfolio, Specification and Application
12.13.3 Gritstone Bio
Neoantigen Vaccine Sales, Price, Revenue and Gross Margin (2019-2021)
12.13.4 Gritstone Bio
Key Development
12.14 Genocea Biosciences Inc
12.14.1 Genocea Biosciences Inc
Company Information
12.14.2 Genocea Biosciences Inc
Neoantigen Vaccine Product Portfolio, Specification and Application
12.14.3 Genocea Biosciences Inc
Neoantigen Vaccine Sales, Price, Revenue and Gross Margin (2019-2021)
12.14.4 Genocea Biosciences Inc
Key Development
12.15 Eli Lilly and Company
12.15.1 Eli Lilly and Company
Company Information
12.15.2 Eli Lilly and Company
Neoantigen Vaccine Product Portfolio, Specification and Application
12.15.3 Eli Lilly and Company
Neoantigen Vaccine Sales, Price, Revenue and Gross Margin (2019-2021)
12.15.4 Eli Lilly and Company
Key Development
12.17 BioNTech
12.18 Avidea Technologies
12.19 Agenus Inc
12.20 Advaxis
13 Global Neoantigen Vaccine Market Forecast by Region by Type and by Application
13.1 Global Neoantigen Vaccine Sales, Revenue Forecast 2022-2027
13.2 Global Neoantigen Vaccine Forecast by Regions
13.2.1 Global Neoantigen Vaccine Sales Forecast by Region 2022-2027
13.2.2 Global Neoantigen Vaccine Revenue Forecast by Region 2022-2027
13.3 Global Neoantigen Vaccine Forecast by Type
13.3.1 Global Neoantigen Vaccine Sales Forecast by Type 2022-2027
13.3.2 Global Neoantigen Vaccine Revenue Forecast by Type 2022-2027
13.3.3 Global Neoantigen Vaccine Price Forecast by Type 2022-2027
13.4 Global Neoantigen Vaccine Forecast by Application
13.4.1 Global Neoantigen Vaccine Sales Forecast by Application 2022-2027
13.4.2 Global Neoantigen Vaccine Revenue Forecast by Application 2022-2027
13.4.3 Global Neoantigen Vaccine Price Forecast by Application 2022-2027
14 Analyst Views and Conclusions
15 Methodology and Data Source
15.1 Methodology
15.2 Research Data Source
15.2.1 Secondary Data
15.2.2 Primary Data
15.2.3 Market Size Estimation
15.3 Legal Disclaimer
NEED Help?
If you need any help or guidance, please feel free to call us.
USA : +1 (661) 636 6162
INDIA : +91 9325802062
or
Write us on : sales@kandjmarketresearch.com